A Phase I, Multicenter Study to Evaluate the Safety, Tolerability, and Efficacy of LCAR-T2C CAR-T Cells in Relapsed or Refractory CD4+ T Lymphocyte Tumor Patients
A Phase I, Multicenter Study to Evaluate the Safety, Tolerability, and Efficacy of LCAR-T2C CAR-T Cells in Relapsed or Refractory CD4+ T Lymphocyte Tumor Patients is a PHASE1 clinical asset sponsored by Beijing Boren Hospital in T Cell Lymphoma, T-cell Leukemia. SEO and diligence focus: Efficacy of LCAR-T2C CAR-T cells, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.
Indication: T Cell Lymphoma
Modality: cell therapy
Target: Efficacy of LCAR-T2C CAR-T cells
Sponsor: Beijing Boren Hospital
Source URL: ClinicalTrials.gov
Source updated: Detailed source ingestion pending
Ingested: Jul 28, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: Efficacy of LCAR-T2C CAR-T cells
View original source fields
Condition raw: T Cell Lymphoma, T-cell Leukemia
Condition normalized: T Cell Lymphoma, T-cell Leukemia
Modality raw: cell therapy
Modality normalized: cell therapy
Target raw: Efficacy of LCAR-T2C CAR-T cells
Target normalized: Efficacy of LCAR-T2C CAR-T cells